Agenus | AGEN - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.89B 325M 2025-12
Agenus USD 10.56M 13.04M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Celldex Therapeutics USD 7.84M 1.21M 2025-12
CSL USD 1.23B 498M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.75B 831M 2025-12
Jiangsu Hengrui CNY 3.23B 111.82M 2025-09
Karyopharm Therapeutics USD 27.19M 442K 2024-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck EUR 1.6B 136M 2025-12
Merck USD 2.85B 215M 2025-12
Northwest Biotherapeutics USD 7.03M 534K 2023-09
Novartis USD 3.44B 128M 2025-12
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 4.08B 894M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Veracyte USD 43.31M 8.43M 2025-12